PRONORAN IN MONOTHERAPY AND COMBINED TREATMENT FOR PARKINSON’S DISEASE

Download full text PDF
Issue: 
4
Year: 
2015

A. Lyubimov, MD; A. Kretova; L. Borzunova, Candidate of Medical Sciences; N. Krol, Candidate of Medical Sciences Voronezh City Clinical Hospital Seven

Pronoran is one of the effective dopamine receptor agonists. It may be successfully used for the therapy of both early- and late-stage Parkinson’s disease, by improving day-to-day motor activity in patients and their quality of life.
Keywords: 
Parkinson’s disease
dopamine receptor agonists
Parkinson’s disease stages

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Geht A.B. Primenenie agonistov dofamina v lechenii bolezni Parkinsona // Zhurn. nevrol. i psihiat. – 2002; 102 (9): 54–8.
  2. Golubev V.L. Lechenie bolezni Parkinsona // Zhurn. lechenie nervn. bol. – 2001; 2 (3): 3–12.
  3. Gusev E.I., Geht A.B. Bolezn' Parkinsona. Osnovnye napravlenija lechenija // Consilium Medicum. – 2000; 2 (2): 67–70.
  4. Levin O.S. Agonisty dofaminovyh retseptorov v lechenii bolezni Parkinsona // Zhurn. lechenie nervn. bol. – 2003; 1 (9): 14–7.
  5. Pilipovich A.A., Golubev V.L. Vlijanie pronorana na kognitivnye i affektivnye narushenija pri bolezni Parkinsona // Zhurn. nevrol. i psi-hiat. – 2005; 105 (4): 41–7.
  6. Fedorova N.V., Artem'eva E.G., Chigir' I.P. i dr. Primenenie pronorana (piribedila) pri bolezni Parkinsona // Zhurn. nevrol. i psihiat. – 2003; 103 (9): 71–2.
  7. Shtok V.N., Fedorova N.V. Sovremennye printsipy lechenija parkinso nizma // Rus. med. zhurn. – 1998; 6 (13): 837–44.
  8. Jahno N.N., Nodel' M.R. Sovremennye printsipy terapii bolezni Parkinsona // Rus. med. zhurn. – 2000; 8 (10): 418–25.
  9. Cagnotto A., Parotti L., Mennini T. In vitro affinity of peribedil for dopamine D3 receptor subtypes, an autoradiographic study // Eur. J. Pharmacol. – 1996; 313: 63–7.
  10. Chrischilles E., Rubenstein L., Voelker M. et al. The health burdens of Parkinson’s disease // Mov. Dis. – 1998; 13: 406–13.
  11. Dodel R., Eggert K., Singer M. et al. Costs of drug treatment in Parkinson’s disease // Mov. Dis. – 1998; 13 (2): 249–54.
  12. Hoerger T., Bala M., Rowland C. et al. Cost effectiveness of pramipexol in Parkinson’s disease in the US // Pharmacoeconomics. – 1998; 14: 541–57.
  13. Maurel F., Lilliu H., Le Pen C. Social and economic cost of L-Dopa-induced dyskinesias in patients with Parkinson’s disease // Rev. Neurol. (Paris). – 2001; 157 (5): 507–14.
  14. Rondot P., Ziegler M. Activity and acceptability of piribedil in Parkinson’s disease: a multicenter study // J. Neurol. – 1992; 239 (Suppl. 1): 28–34.